all for Thank you, today. joining you Tiffany, and thank us
as X share excited novel programs as of in the well regarding presentation. We will our OCUXXX candidate, highlight gene biologic clinical progress are recent our the across later modifier platform ongoing I announcement all to therapy which
FDA the U.S. clinical OCUXXX adult retinitis third patients the aged regulatory the with we from Canada Phase Health milestones, RP, and expanded using for for to and treatment access program, in approval XX pigmentosa, quarter, an OCUXXX. and notable or EAP, from Canada III-liMeliGhT accomplished initiate older trial approval clinical the including During of
to life living and RP. consistent are trial the for providing closer These treatment potential company patients even accomplishments to bringing with onetime enrollment
planned. gene. trials RORA advancing OCUXXXST the OCUXXX clinical gene through leveraging modifier Our and their programs, respective as therapy are
We of age-related atrophy, geographic are trial currently in ArMaDa II an advanced OCUXXX stage degeneration, dosing of clinical for the GA, macular patients Phase dAMD. treatment dry
disease, the Monitoring and Stargardt and Phase FDA trial. clinical the enrollment remains dosing trial I safety Phase inherited the The approved retinal for favorable medical unmet large completed profile. a approved Phase is currently second the tolerability Board, We in most of need DSMB, there phase a clinical OCUXXXST/GARDian Safety with the with treatment. common I/II disease Data no I/II
of Avenue inflection forward a to closing in points. that from quarter debt $XX confident therapy our we achieving and Group. first NRXEX achievements week, of secured the the into these runway that OCUXXX, This financing announced candidate our million by lead Phase is gene. encouraged for liMeliGhT This utilizes path XXXX. extend well trial our underway pivotal gene clinical funding near-term in Dosing to an I'm III expected our the Capital is
we the numerous previously initiate it the for is OCUXXX mentioned, to for clinical received Ocugen significant to associated Canada broader III Health trial in mutations with Canada. patient a clinical Phase to us trial opportunity a population approval As allow will RP. Canada as Expanding encompassing reach gene
of plan this X United and enroll sites in and the the commercialization to of across a expediting maximum States Europe. gene-agnostic subjects We recruitment, broadening treatment potential
OCUXXX III forward is for XX EAP and approval also it treatment aged beyond clinical for a meaningful patients for RP OCUXXX wider also for therapeutic safety trial. to to patients a an qualifying data trial, in EAP FDA desperate Phase clinical offering makes the our validate approval hope This previous I/II the received patients of step as population generated a with The Phase option. older. the of positive available adult OCUXXX and serves optimism
gene Phase of file of to MAA, treat Europe in regardless the clinical commercialization complete half application, III first of patients The XXXX, III with RP this track Phase is mutation. biologics and BLA, in pursue on XXXX. license application, in authorization trial the candidate market first Furthermore, in the first therapy the to half XXXX, is enrollment and
market one that the and There affected moment the in Canada underdeserved patients. a approximately to by are gene disease. in the development caused mutation need Let each patients approved this roughly one RP with on and by is market are address me therapy which XXX highlight for different unmet XXX,XXX genes. associated Europe disease, U.S., take currently only and the in mutations The
modified patient potential for provide of with treatment than this its overall master the health. retina new totally Rather one-to-one category of a are showcased the therapy underserved and many a associated optogenetics regulators, of gene to approach. genes using in through its gene-agnostic population. use candidates Other network functional targets the including very small only disease approach, development, has resetting OCUXXX gene intended restoring
differentiated over therapies. its the key about mechanism our continue of of therapy and extensive gene We modifier stakeholders action current advantages indicate our campaign platform, to
meetings the our Gene we as significant had updates provide to on Mesa, Cell and quarter, hosted during decision-makers as like audiences the Alliance third clinical-stage to Regenerative opportunity on the for Medicine. gene X industry modifier therapies by During the well Meeting investor
Now in development be to the to dAMD, which disease, with onetime our treatment to secondary OCUXXX life a injection, move patients GA and blindness OCUXXXST, a and Stargardt on could debilitating respectively, aim treat for these let's subretinal that diseases. for living with single
X of to specifically by treatment Currently and target dAMD safety options year pathways is XX per doses the only approved designed over offer one various complement OCUXXX about implicated are frequent intravitreal treatment and options system. address current in require advantages distinct accompanied pathway, the pathogenesis multiple concerns. that to injections,
roughly XX% example, AMD For wet following of patients treatment. develop
metabolism, the to has addressing X million to primed a Europe in entrants, OCUXXX X inflammation, potential stress OCUXXX current the patients complement the that the with system, disease thereby combined, new progression, oxidative given to X related underlying GA pathways lipid and With shortcomings the for million causes of U.S. therapies. the regulate is represents the approximately all market disease. and considerable
Additionally, there in GA is no approved product Europe. for
trial, of plan We complete the are currently early in to in Phase dosing Phase and I/II ArMaDa XXXX. II clinical
at GA SAEs X OCUXXX I/II treated profile. the study, and and XXX date, with safety been and trial be A next the to patients To safety To and upcoming Phase low, serious showcase have clinical the tolerability OCUXXX reported. been events, no medium Phase with ArMaDa efficacy shared preliminary on demonstrated will doses week. update a OCUXXX related date, high I in favorable have the clinical
older, OCUXXX of efficacy will into Phase of a the an patients, X square Participants recruiting untreated medium-dose expansion, in high-dose between a like who SSR-blinded to a XX group patients total more groups: atrophy the BCVA, randomized of which X and group. XX.X clinical you a at II office safety aged be identify treatment assess and or will on XX The a letters geographic dose control must treatment area charts read and X.X trial group, millimeters. able and larger have be group optometrist is on or be is
the dosing orphan Phase profile. disease. clinical of FDA designation of favorable been OCUXXXST, ABCAX-associated has safety a GARDian which demonstrated the from has and retinopathies, I/II drug and to on received Stargardt OCUXXXST the I Turning completed Phase including for trial treatment tolerability
OCUXXXST person's has available. of condition the the no approved soft lifetime. bilateral gradually trial. to II over Stargardt XXX,XXX people therapy SAAs have to Board This and form and macular most Data affects dystrophy typically Phase reported. is clinical The worsening is To childhood, no proceeding inherited Safety symptom and a approved [ common approximately forming loss disease during in Europe, been U.S. of Monitoring central related and date, the ] with vision
showcase. A clinical at trial preliminary update the GARDian OCUXXXST the Phase efficacy and also featured be will clinical on safety upcoming I/II
of features application unique the attention Lastly, and to announced FDA I recent consisting platform complications that DME. edema, biologic to the it for DME. of XXX,XXX address. progressive the more with patients prevalent condition number with imperative blurriness diabetic vascular OCUXXX, tumstatin we fusion OCUXXX, advances. for in I U.S. possesses would macular affected people transferrin The as are of evaluating to diabetes In in DME. the cleared disease our treat States treatment call trial more of loss a investigational recombinant protein the drug vision clinical is making news, DME vision the which Phase Approximately a like and in causes as raises, United to the becoming the
OCUXXX refractive the to has therapies, people nonresponders and potential current with of to new XX% option including provide DME, believe to are Approximately living treatment the significant current XX% standard for care. we that DME a anti-VEGF percentage of a patients to
trial of initiate We Phase this I plan quarter. to clinical OCUXXX
focusing to to ended clinical will the we update provide XXXX. therapies over aim Ramesh Our these treating Ramesh? Ramachandran to further benefits. commitment advance to turn blindness an as updates lasting provide platforms patient on for on financial our that quarter results forward look diseases, We efforts I our across development. now innovative represent XX, September through solutions call sharing the to
